CA3233239A1 - High-throughput methods for preparing lipid nanoparticles and uses thereof - Google Patents

High-throughput methods for preparing lipid nanoparticles and uses thereof Download PDF

Info

Publication number
CA3233239A1
CA3233239A1 CA3233239A CA3233239A CA3233239A1 CA 3233239 A1 CA3233239 A1 CA 3233239A1 CA 3233239 A CA3233239 A CA 3233239A CA 3233239 A CA3233239 A CA 3233239A CA 3233239 A1 CA3233239 A1 CA 3233239A1
Authority
CA
Canada
Prior art keywords
lipid
payload
solution
lnp
varied
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233239A
Other languages
English (en)
French (fr)
Inventor
Yuchen FAN
Chun-Wan YEN
Ke Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA3233239A1 publication Critical patent/CA3233239A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
CA3233239A 2021-10-26 2022-10-26 High-throughput methods for preparing lipid nanoparticles and uses thereof Pending CA3233239A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272136P 2021-10-26 2021-10-26
US63/272,136 2021-10-26
PCT/US2022/078710 WO2023076945A1 (en) 2021-10-26 2022-10-26 High-throughput methods for preparing lipid nanoparticles and uses thereof

Publications (1)

Publication Number Publication Date
CA3233239A1 true CA3233239A1 (en) 2023-05-04

Family

ID=86158549

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233239A Pending CA3233239A1 (en) 2021-10-26 2022-10-26 High-throughput methods for preparing lipid nanoparticles and uses thereof

Country Status (12)

Country Link
US (1) US20240390287A1 (https=)
EP (1) EP4422606A4 (https=)
JP (1) JP2024541897A (https=)
KR (1) KR20240090304A (https=)
CN (1) CN118139616A (https=)
AR (1) AR127469A1 (https=)
AU (1) AU2022376919A1 (https=)
CA (1) CA3233239A1 (https=)
IL (1) IL311945A (https=)
MX (1) MX2024004733A (https=)
TW (1) TW202333653A (https=)
WO (1) WO2023076945A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120722759B (zh) * 2025-08-28 2025-11-21 深圳市一五零生命科技有限公司 复方利多卡因纳米凝胶的制备工艺优化方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120392779A (zh) * 2015-06-15 2025-08-01 华盛顿大学 用于延长血液和淋巴组织中的药物水平的多药脂质纳米颗粒组合物和相关方法
WO2017223135A1 (en) * 2016-06-24 2017-12-28 Modernatx, Inc. Lipid nanoparticles
US20230157955A1 (en) * 2020-01-08 2023-05-25 Puretech Lyt, Inc. Vesicle compositions for oral delivery
TW202237068A (zh) * 2020-12-09 2022-10-01 美商建南德克公司 製備脂質奈米顆粒的高通量方法及其用途

Also Published As

Publication number Publication date
US20240390287A1 (en) 2024-11-28
AR127469A1 (es) 2024-01-31
WO2023076945A1 (en) 2023-05-04
KR20240090304A (ko) 2024-06-21
IL311945A (en) 2024-06-01
EP4422606A4 (en) 2025-09-17
WO2023076945A9 (en) 2025-02-13
JP2024541897A (ja) 2024-11-13
EP4422606A1 (en) 2024-09-04
TW202333653A (zh) 2023-09-01
CN118139616A (zh) 2024-06-04
AU2022376919A1 (en) 2024-03-21
MX2024004733A (es) 2024-05-10

Similar Documents

Publication Publication Date Title
US20230330023A1 (en) High-throughput methods for preparing lipid nanoparticles and uses thereof
Liu et al. A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives
John et al. Chemistry and art of developing lipid nanoparticles for biologics delivery: focus on development and scale-up
Fan et al. Automated high-throughput preparation and characterization of oligonucleotide-loaded lipid nanoparticles
Ishida et al. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes
US11072629B2 (en) Reprogramming of cellular adhesion
Shende et al. Nanostructured cochleates: A multi-layered platform for cellular transportation of therapeutics
Zhou et al. SPANosomes as delivery vehicles for small interfering RNA (siRNA)
US20240390287A1 (en) High-throughput methods for preparing lipid nanoparticles and uses thereof
EP3074047A2 (en) Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery
JP7826197B2 (ja) オルニチントランスカルバミラーゼ（ｏｔｃ）構築物およびそれを使用する方法
AU2020269626A1 (en) Method for production of liposomes
WO2022266083A2 (en) Engineered polynucleotides for cell-type or microenvironment-specific expression
Hameed et al. Liposomes like advanced drug carriers: from fundamentals to pharmaceutical applications
Omo-Lamai et al. RNA–lipid nanoparticles for acute critical illnesses
EP4442256A1 (en) Lipid nanoparticle compositions
KR20230022415A (ko) 지질-중합체 조성물 및 사용 방법
HK40110520A (zh) 用於制备脂质纳米颗粒的高通量方法及其用途
HK40101719A (zh) 用於制备脂质纳米颗粒的高通量方法及其用途
CN120769913A (zh) 基于核酸的癌症疫苗及其方法
Giacobbo End-to-end optimization of lipid nanoparticle manufacturing for mRNA delivery
US20260035707A1 (en) Engineered polynucleotides for temporal control of expression
Patel et al. Potential of surface functionalized nanoparticles for improved therapy of refractory central nervous system disorders
WO2025217087A1 (en) Lipid nanoparticles for intracellular delivery of proteins
CN121152620A (zh) 用含聚噁唑啉-脂质缀合物的纳米颗粒靶向抗原呈递细胞

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240930

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240930

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250925

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250925